{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T22:20:06Z","timestamp":1794608406406,"version":"4.9.1"},"reference-count":136,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.beem.2024.101909","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T07:02:48Z","timestamp":1719385368000},"page":"101909","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["The implications of hormone treatment for cancer risk, screening and treatment in transgender individuals"],"prefix":"10.1016","volume":"38","author":[{"given":"Alison May","family":"Berner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Elizabeth","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2024.101909_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2018.02.008","article-title":"Frequency and distribution of primary site among gender minority cancer patients: an analysis of U.S. National Surveillance Data","volume":"54","author":"Nash","year":"2018","journal-title":"Cancer Epidemiol"},{"issue":"9","key":"10.1016\/j.beem.2024.101909_bib2","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djab028","article-title":"Cancer stage, treatment, and survival among transgender patients in the United States","volume":"113","author":"Jackson","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.beem.2024.101909_bib3","article-title":"Breast cancer risk in transgender people receiving hormone treatment: Nationwide cohort study in the Netherlands","volume":"365","author":"De Blok","year":"2019","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.beem.2024.101909_bib4","article-title":"Prostate cancer incidence under androgen deprivation: nationwide cohort study in trans women receiving hormone treatment","volume":"105","author":"Nie","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2024.101909_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.trecan.2022.01.013","article-title":"The spectrum of sex differences in cancer","volume":"8","author":"Rubin","year":"2022","journal-title":"Trends Cancer"},{"issue":"8","key":"10.1016\/j.beem.2024.101909_bib6","article-title":"Endogenous sex hormones and breast cancer in postmenopausal women: Reanalysis of nine prospective studies","volume":"94","author":"Key","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.beem.2024.101909_bib7","article-title":"Progesterone and breast cancer","volume":"4","author":"Lange","year":"2008","journal-title":"Women\u2019s Health"},{"issue":"3","key":"10.1016\/j.beem.2024.101909_bib8","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3422","article-title":"Progesterone metabolites regulate induction, growth, and suppression of estrogen- and progesterone receptor-negative human breast cell tumors","volume":"15","author":"Wiebe","year":"2013","journal-title":"Breast Cancer Res"},{"issue":"4","key":"10.1016\/j.beem.2024.101909_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.3645","article-title":"Association of circulating progesterone with breast cancer risk among postmenopausal women","volume":"3","author":"Trabert","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"9084","key":"10.1016\/j.beem.2024.101909_bib10","article-title":"Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer","volume":"350","author":"Calle","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2024.101909_bib11","article-title":"Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases","volume":"371","author":"Vinogradova","year":"2020","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.beem.2024.101909_bib12","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114314","article-title":"Contraceptive progestins with androgenic properties stimulate breast epithelial cell proliferation","volume":"13","author":"Shamseddin","year":"2021","journal-title":"EMBO Mol Med"},{"issue":"2","key":"10.1016\/j.beem.2024.101909_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-020-0751-5","article-title":"Using human genetics to understand the disease impacts of testosterone in men and women","volume":"26","author":"Ruth","year":"2020","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.beem.2024.101909_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/s41416-021-01392-z","article-title":"Endogenous hormones and risk of invasive breast cancer in pre- and post-menopausal women: findings from the UK Biobank","volume":"125","author":"Tin Tin","year":"2021","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.beem.2024.101909_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/jsm.12319","article-title":"Breast cancer development in transsexual subjects receiving cross-sex hormone treatment","volume":"10","author":"Gooren","year":"2013","journal-title":"J Sex Med"},{"issue":"1","key":"10.1016\/j.beem.2024.101909_bib16","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-014-3213-2","article-title":"Incidence of breast cancer in a cohort of 5,135 transgender veterans","volume":"149","author":"Brown","year":"2015","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"10.1016\/j.beem.2024.101909_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.annepidem.2017.07.007","article-title":"Cohort study of cancer risk among insured transgender people","volume":"27","author":"Silverberg","year":"2017","journal-title":"Ann Epidemiol"},{"issue":"3","key":"10.1016\/j.beem.2024.101909_bib18","article-title":"The molecular consequences of androgen activity in the human breast","volume":"3","author":"Raths","year":"2023","journal-title":"Cell Genom"},{"issue":"4","key":"10.1016\/j.beem.2024.101909_bib19","article-title":"Studies on prostatic cancer i. the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"1","author":"Huggins","year":"1941","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.beem.2024.101909_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2018.07.024","article-title":"Low free testosterone and prostate cancer risk: a collaborative analysis of 20 prospective studies","volume":"74","author":"Watts","year":"2018","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.beem.2024.101909_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/pros.2990180206","article-title":"A comparison of Zoladex\u00ae and DES in the treatment of advanced prostate cancer: Results of a randomized, multicenter trial","volume":"18","author":"Citrin","year":"1991","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/j.beem.2024.101909_bib22","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.2820","article-title":"Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity","volume":"6","author":"Takizawa","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.beem.2024.101909_bib23","doi-asserted-by":"crossref","DOI":"10.4103\/1008-682X.136445","article-title":"Estrogen receptor (\u03b1 and \u03b2) but not androgen receptor expression is correlated with recurrence, progression and survival in post prostatectomy T3N0M0 locally advanced prostate cancer in an urban Greek population","volume":"17","author":"Megas","year":"2015","journal-title":"Asian J Androl"},{"issue":"1","key":"10.1016\/j.beem.2024.101909_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/pros.2990250103","article-title":"Estrogen treatment postpones the castration\u2010induced dedifferentiation of dunning R3327\u2010PAP prostatic adenocarcinoma","volume":"25","author":"Landstr\u00f6m","year":"1994","journal-title":"Prostate"},{"issue":"10","key":"10.1016\/j.beem.2024.101909_bib25","doi-asserted-by":"crossref","DOI":"10.1111\/and.12208","article-title":"Prostate cancer incidence in orchidectomised male-to-female transsexual persons treated with oestrogens","volume":"46","author":"Gooren","year":"2014","journal-title":"Andrologia"},{"key":"10.1016\/j.beem.2024.101909_bib26","article-title":"Incidence of prostate cancer in transgender women in the US: a large database analysis","author":"Loria","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.beem.2024.101909_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/s41391-024-00839-7","article-title":"Methodological considerations in the use of a large database to estimate incidence of prostate cancer in transgender women in the US","author":"Berner","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.beem.2024.101909_bib28","doi-asserted-by":"crossref","DOI":"10.1172\/JCI170809","article-title":"The estrogen signaling pathway reprograms prostate cancer cell metabolism and supports proliferation and disease progression","author":"Lafront","year":"2024","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.beem.2024.101909_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232231","article-title":"Concurrent and future risk of endometrial cancer in women with endometrial hyperplasia: a systematic review and meta-analysis","volume":"15","author":"Doherty","year":"2020","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.beem.2024.101909_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.11529","article-title":"Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women","volume":"108","author":"Lukanova","year":"2004","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.beem.2024.101909_bib31","doi-asserted-by":"crossref","DOI":"10.1677\/ERC-07-0064","article-title":"Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC)","volume":"15","author":"Allen","year":"2008","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"10.1016\/j.beem.2024.101909_bib32","doi-asserted-by":"crossref","DOI":"10.1093\/humrep\/des042","article-title":"Evaluating the association between endometrial cancer and polycystic ovary syndrome","volume":"27","author":"Haoula","year":"2012","journal-title":"Hum Reprod"},{"issue":"2","key":"10.1016\/j.beem.2024.101909_bib33","article-title":"Ultrasound and menstrual history in predicting endometrial hyperplasia in polycystic ovary syndrome","volume":"98","author":"Cheung","year":"2001","journal-title":"Obstet Gynecol"},{"issue":"9","key":"10.1016\/j.beem.2024.101909_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.tem.2022.06.001","article-title":"Integration of androgen hormones in endometrial cancer biology","volume":"33","author":"Gjorgoska","year":"2022","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2024.101909_bib35","doi-asserted-by":"crossref","DOI":"10.1210\/jcem-62-1-16","article-title":"Histopathological effects of exogenously administered testosterone in 19 female to male transsexuals","volume":"62","author":"Futterweit","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.beem.2024.101909_bib36","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2559.1986.tb02520.x","article-title":"Histological changes in the genital tract in transsexual women following androgen therapy","volume":"10","author":"Miller","year":"1986","journal-title":"Histopathology"},{"issue":"3","key":"10.1016\/j.beem.2024.101909_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2018.12.021","article-title":"Uterine pathology in transmasculine persons on testosterone: a retrospective multicenter case series","volume":"220","author":"Grimstad","year":"2019","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.beem.2024.101909_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.rbmo.2009.12.021","article-title":"Histology of genital tract and breast tissue after long-term testosterone administration in a female-to-male transsexual population","volume":"20","author":"Grynberg","year":"2010","journal-title":"Reprod Biomed Online"},{"issue":"5","key":"10.1016\/j.beem.2024.101909_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjog.2016.03.004","article-title":"Uterine and ovarian changes during testosterone administration in young female-to-male transsexuals","volume":"55","author":"Loverro","year":"2016","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.beem.2024.101909_bib40","unstructured":"Cancer.Net. Uterine Cancer Statistics. American Society of Clinical Oncology (ASCO). Published 2024. [Accessed May 17, 2024]. \u3008https:\/\/www.cancer.net\/cancer-types\/uterine-cancer\/statistics\u3009."},{"issue":"3","key":"10.1016\/j.beem.2024.101909_bib41","doi-asserted-by":"crossref","DOI":"10.21037\/tau.2019.04.09","article-title":"Demographic and temporal trends in transgender identities and gender confirming surgery","volume":"8","author":"Nolan","year":"2019","journal-title":"Transl Androl Urol"},{"issue":"7","key":"10.1016\/j.beem.2024.101909_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15072062","article-title":"Increased local testosterone levels alter human fallopian tube mRNA profile and signaling","volume":"15","author":"Russo","year":"2023","journal-title":"Cancers"},{"issue":"14","key":"10.1016\/j.beem.2024.101909_bib43","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-16-3322","article-title":"Androgens are differentially associated with ovarian cancer subtypes in the Ovarian Cancer Cohort Consortium","volume":"77","author":"Ose","year":"2017","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.beem.2024.101909_bib44","article-title":"Cervical carcinoma and reproductive factors: Collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies","volume":"119","author":"Rajkumar","year":"2006","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.beem.2024.101909_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147029","article-title":"The influence of hormonal factors on the risk of developing cervical cancer and pre-cancer: results from the EPIC cohort","volume":"11","author":"Roura","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.beem.2024.101909_bib46","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-022-09247-3","article-title":"Endogenous oestradiol and progesterone as predictors of oncogenic human papillomavirus (HPV) persistence","volume":"22","author":"Fischer","year":"2022","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.beem.2024.101909_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23095050","article-title":"Like brothers in arms: how hormonal stimuli and changes in the metabolism signaling cooperate, leading HPV infection to drive the onset of cervical cancer","volume":"23","author":"L\u00e4sche","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.beem.2024.101909_bib48","article-title":"Association of serum concentrations of testosterone and insulin with the degree of cervical squamous intraepithelial lesions in cuban women","volume":"4","author":"Maydelin","year":"2022","journal-title":"J Cerv Cancer Res"},{"issue":"4","key":"10.1016\/j.beem.2024.101909_bib49","first-page":"128","article-title":"Comparing human papillomavirus prevalence in rectal and anal cancer using US cancer registries, 2014-2015","volume":"46","author":"Mix","year":"2019","journal-title":"J Regist Manag"},{"issue":"11","key":"10.1016\/j.beem.2024.101909_bib50","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/93.11.843","article-title":"Prevalence and risk factors for anal squamous intraepithelial lesions in women","volume":"93","author":"Holly","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.beem.2024.101909_bib51","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jis458","article-title":"Prevalence of and risk factors for anal human papillomavirus infection among young healthy women in costa rica","volume":"Vol 206","author":"Castro","year":"2012","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.beem.2024.101909_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(99)70456-7","article-title":"Prevalence and ethnic differences in gallbladder disease in the United States","volume":"117","author":"Everhart","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.beem.2024.101909_bib53","unstructured":"Ferlay J., Ervik M., Lam F., et al. (IARC) IAfRoC Anus Fact sheet. Global Cancer Observatory: Cancer Today. Published 2024. Accessed May 17, 2024. \u3008https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/10-anus-fact-sheet.pdf\u3009."},{"issue":"9","key":"10.1016\/j.beem.2024.101909_bib54","doi-asserted-by":"crossref","DOI":"10.1086\/651620","article-title":"Sequential acquisition of human papillomavirus (HPV) infection of the anus and cervix: The Hawaii HPV cohort study","volume":"201","author":"Goodman","year":"2010","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.beem.2024.101909_bib55","doi-asserted-by":"crossref","DOI":"10.1086\/529207","article-title":"Acquisition of anal human papillomavirus (HPV) infection in women: the Hawaii HPV cohort study","volume":"197","author":"Goodman","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.beem.2024.101909_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.pvr.2018.07.035","article-title":"Serum testosterone and estradiol modify risk of anal HPV16\/18 infections but only estradiol influences risk for histological high-grade squamous intraepithelial lesions (HSIL)","volume":"5","author":"Wiley","year":"2018","journal-title":"Papillomavirus Res"},{"issue":"3","key":"10.1016\/j.beem.2024.101909_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119447","article-title":"Association between free testosterone levels and anal human papillomavirus Types 16\/18 infections in a cohort of men who have sex with men","volume":"10","author":"Hsu","year":"2015","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.beem.2024.101909_bib58","doi-asserted-by":"crossref","DOI":"10.1097\/OLQ.0000000000001051","article-title":"Transgender women have higher human papillomavirus prevalence than men who have sex with men-two U.S. Cities, 2012-2014","volume":"46","author":"Singh","year":"2019","journal-title":"Sex Transm Dis"},{"issue":"8","key":"10.1016\/j.beem.2024.101909_bib59","doi-asserted-by":"crossref","DOI":"10.1097\/OLQ.0000000000001388","article-title":"Neovaginal and anal high-risk human papillomavirus DNA among Thai transgender women in gender health clinics","volume":"48","author":"Uaamnuichai","year":"2021","journal-title":"Sex Transm Dis"},{"issue":"2","key":"10.1016\/j.beem.2024.101909_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2011.03.008","article-title":"Human Papilloma virus genotype diversity of anal infection among trans (male to female transvestites, transsexuals or transgender) sex workers in Argentina","volume":"51","author":"dos Ramos Far\u00edas","year":"2011","journal-title":"J Clin Virol"},{"key":"10.1016\/j.beem.2024.101909_bib61","article-title":"Meningiomas: a review of general, histopathological, clinical and molecular characteristics","volume":"223","author":"Salles","year":"2021","journal-title":"Pathol Res Pr"},{"issue":"65","key":"10.1016\/j.beem.2024.101909_bib62","article-title":"The molecular biology of hormone and growth factor receptors in meningiomas","volume":"1996","author":"Black","year":"1996","journal-title":"Acta Neurochir Suppl"},{"issue":"2","key":"10.1016\/j.beem.2024.101909_bib63","doi-asserted-by":"crossref","DOI":"10.1023\/A:1006158514866","article-title":"Expression of estrogen receptors alpha and beta in human meningiomas","volume":"42","author":"Carroll","year":"1999","journal-title":"J Neurooncol"},{"issue":"5","key":"10.1016\/j.beem.2024.101909_bib64","doi-asserted-by":"crossref","DOI":"10.3171\/jns.2003.99.5.0848","article-title":"Sex steroid hormone exposures and risk for meningioma","volume":"99","author":"Jhawar","year":"2003","journal-title":"J Neurosurg"},{"key":"10.1016\/j.beem.2024.101909_bib65","article-title":"Use of high dose cyproterone acetate and risk of intracranial meningioma in women: Cohort study","volume":"372","author":"Weill","year":"2021","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.beem.2024.101909_bib66","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awy108","article-title":"The occurrence of benign brain tumours in transgender individuals during cross-sex hormone treatment","volume":"141","author":"Nota","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.beem.2024.101909_bib67","unstructured":"European Medicines Agency. Cyproterone-containing medicinal products - referral. European Medicines Agency."},{"issue":"11","key":"10.1016\/j.beem.2024.101909_bib68","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2017-01658","article-title":"Endocrine treatment of gender-dysphoric\/ gender-incongruent persons: An endocrine society\u2217clinical practice guideline","volume":"102","author":"Hembree","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101909_bib69","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1080\/26895269.2022.2100644","article-title":"Standards of care for the health of transgender and gender diverse people, version 8","volume":"23","author":"Coleman","year":"2022","journal-title":"Int J Transgend Health"},{"key":"10.1016\/j.beem.2024.101909_bib70","unstructured":"Deutsch M.B.. University of California San Francisco. Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People. 2nd edition - Screening for breast cancer in transgender women. The Regents of the University of California. Published June 17, 2016. Accessed May 1, 2024. \u3008https:\/\/transcare.ucsf.edu\/guidelines\/breast-cancer-women\u3009."},{"issue":"8","key":"10.1016\/j.beem.2024.101909_bib71","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.21505","article-title":"Evaluation of adjunctive ultrasonography for breast cancer detection among women aged 40-49 years with varying breast density undergoing screening mammography: a secondary analysis of a randomized clinical trial","volume":"4","author":"Harada-Shoji","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.beem.2024.101909_bib72","doi-asserted-by":"crossref","DOI":"10.1148\/rg.2020190044","article-title":"Breast imaging in transgender patients: what the radiologist should know","volume":"40","author":"Parikh","year":"2020","journal-title":"Radiographics"},{"key":"10.1016\/j.beem.2024.101909_bib73","article-title":"Barriers and facilitators to cervical cancer screening among transgender men and non-binary people with a cervix: a systematic narrative review","volume":"135","author":"Connolly","year":"2020","journal-title":"Prev Med (Balt)"},{"issue":"6","key":"10.1016\/j.beem.2024.101909_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.amepre.2014.07.031","article-title":"Pap test use is lower among female-to-male patients than non-transgender women","volume":"47","author":"Peitzmeier","year":"2014","journal-title":"Am J Prev Med"},{"issue":"3","key":"10.1016\/j.beem.2024.101909_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.amepre.2017.11.009","article-title":"Gender identity disparities in cancer screening behaviors","volume":"54","author":"Tabaac","year":"2018","journal-title":"Am J Prev Med"},{"issue":"5","key":"10.1016\/j.beem.2024.101909_bib76","doi-asserted-by":"crossref","DOI":"10.1007\/s11606-013-2753-1","article-title":"Female-to-male patients have high prevalence of unsatisfactory paps compared to non-transgender females: implications for cervical cancer screening","volume":"29","author":"Peitzmeier","year":"2014","journal-title":"J Gen Intern Med"},{"issue":"4","key":"10.1016\/j.beem.2024.101909_bib77","article-title":"Understanding sexual and gender minority populations and organ-based screening recommendations for human papillomavirus-related cancers","volume":"27","author":"Jodry","year":"2023","journal-title":"J Low Genit Trac Dis"},{"issue":"4","key":"10.1016\/j.beem.2024.101909_bib78","doi-asserted-by":"crossref","DOI":"10.1089\/lgbt.2016.0187","article-title":"Cervical cancer screening preferences among trans-masculine individuals: patient-collected human papillomavirus vaginal swabs versus provider-administered pap tests","volume":"4","author":"McDowell","year":"2017","journal-title":"LGBT Health"},{"key":"10.1016\/j.beem.2024.101909_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101702","article-title":"HPV screening in the urine of transpeople - a prevalence study","volume":"54","author":"Pils","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"2","key":"10.1016\/j.beem.2024.101909_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.path.2022.02.013","article-title":"Reproductive organ pathology of individuals undergoing gender-affirming surgery","volume":"15","author":"Kelley","year":"2022","journal-title":"Surg Pathol Clin"},{"issue":"10","key":"10.1016\/j.beem.2024.101909_bib81","doi-asserted-by":"crossref","DOI":"10.1002\/cncy.22731","article-title":"Cervicovaginal Papanicolaou tests in transgender men: cytomorphologic alterations, interpretation considerations, and clinical implications","volume":"131","author":"Torous","year":"2023","journal-title":"Cancer Cytopathol"},{"issue":"6","key":"10.1016\/j.beem.2024.101909_bib82","doi-asserted-by":"crossref","DOI":"10.1097\/PGP.0000000000000548","article-title":"Histologic features of hysterectomy specimens from female-male transgender individuals","volume":"38","author":"Khalifa","year":"2019","journal-title":"Int J Gynecol Pathol"},{"issue":"10316","key":"10.1016\/j.beem.2024.101909_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(21)02178-4","article-title":"The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study","volume":"398","author":"Falcaro","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.beem.2024.101909_bib84","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.34850","article-title":"International Anal Neoplasia Society\u2019s consensus guidelines for anal cancer screening","volume":"154","author":"Stier","year":"2024","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.beem.2024.101909_bib85","doi-asserted-by":"crossref","DOI":"10.1002\/uog.12306","article-title":"Capacity of endometrial thickness measurement to diagnose endometrial carcinoma in asymptomatic postmenopausal women: a systematic review and meta-analysis","volume":"40","author":"Breijer","year":"2012","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.beem.2024.101909_bib86","doi-asserted-by":"crossref","DOI":"10.1111\/1471-0528.16432","article-title":"A mismatch in care: results of a United Kingdom-wide patient and clinician survey of gynaecological services for women with Lynch syndrome","volume":"128","author":"Ryan","year":"2021","journal-title":"BJOG"},{"issue":"12","key":"10.1016\/j.beem.2024.101909_bib87","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2020-001860","article-title":"Transgender patients: considerations for routine gynecologic care and cancer screening","volume":"30","author":"Labanca","year":"2020","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"10.1016\/j.beem.2024.101909_bib88","doi-asserted-by":"crossref","DOI":"10.21037\/tau-20-954","article-title":"Cancer screening in the transgender population: a review of current guidelines, best practices, and a proposed care model","volume":"9","author":"Sterling","year":"2021","journal-title":"Transl Androl Urol"},{"issue":"3","key":"10.1016\/j.beem.2024.101909_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2007.10.047","article-title":"Early detection of prostate cancer in 2007. Part 1: PSA and PSA Kinetics","volume":"53","author":"Schr\u00f6der","year":"2008","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.beem.2024.101909_bib90","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-021-02230-y","article-title":"Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients","volume":"20","author":"Merriel","year":"2022","journal-title":"BMC Med"},{"issue":"6","key":"10.1016\/j.beem.2024.101909_bib91","doi-asserted-by":"crossref","DOI":"10.1038\/s41585-023-00780-9","article-title":"Prostate cancer is not just a man\u2019s concern \u2014 the use of PSA screening in transgender women","volume":"20","author":"Nik-Ahd","year":"2023","journal-title":"Nat Rev Urol"},{"issue":"12","key":"10.1016\/j.beem.2024.101909_bib92","doi-asserted-by":"crossref","DOI":"10.1210\/jcem.81.12.8954029","article-title":"Androgen or estrogen effects on human prostate","volume":"81","author":"Jin","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.beem.2024.101909_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-5347(05)67808-1","article-title":"Dramatic suppression of plasma and urinary prostate specific antigen and human glandular kallikrein by antiandrogens in male-to-female transsexuals","volume":"163","author":"Obiezu","year":"2000","journal-title":"J Urol"},{"issue":"7","key":"10.1016\/j.beem.2024.101909_bib94","doi-asserted-by":"crossref","DOI":"10.1373\/clinchem.2006.068932","article-title":"Serum and urine tissue kallikrein concentrations in male-to-female transsexuals treated with antiandrogens and estrogens","volume":"52","author":"Slagter","year":"2006","journal-title":"Clin Chem"},{"issue":"10","key":"10.1016\/j.beem.2024.101909_bib95","doi-asserted-by":"crossref","DOI":"10.1111\/jsm.12266","article-title":"Serum PSA as a predictor of testosterone deficiency","volume":"10","author":"Rastrelli","year":"2013","journal-title":"J Sex Med"},{"issue":"2","key":"10.1016\/j.beem.2024.101909_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2013.04.119","article-title":"Early detection of prostate cancer: AUA guideline","volume":"190","author":"Carter","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.beem.2024.101909_bib97","unstructured":"Mottet N., Bergh R.C.N. van den, Briers E., et al. EAU-ESUR-ESTRO-SIOG Guidelines on Prostate Cancer\/ Guias Europeas. European Association of Urology 2018. Published online 2018."},{"issue":"2","key":"10.1016\/j.beem.2024.101909_bib98","doi-asserted-by":"crossref","DOI":"10.1038\/s41416-022-01989-y","article-title":"Prostate cancer in transgender women: considerations for screening, diagnosis and management","volume":"128","author":"Crowley","year":"2023","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.beem.2024.101909_bib99","doi-asserted-by":"crossref","DOI":"10.1002\/nbm.3696","article-title":"Improved multiparametric MRI discrimination between low-risk prostate cancer and benign tissues in a small cohort of 5\u03b1-reductase inhibitor treated individuals as compared with an untreated cohort.","volume":"30","author":"Starobinets","year":"2017","journal-title":"NMR Biomed"},{"key":"10.1016\/j.beem.2024.101909_bib100","unstructured":"56DeanStreet. UK Cancer and Transition Service. 56DeanStreet. Published June 2022. Accessed May 1, 2024. \u3008https:\/\/www.wearetransplus.co.uk\/uk-cancer-and-transition-service\/\u3009."},{"key":"10.1016\/j.beem.2024.101909_bib101","article-title":"Sex differences in drug disposition","volume":"2011","author":"Soldin","year":"2011","journal-title":"J Biomed Biotechnol"},{"issue":"2","key":"10.1016\/j.beem.2024.101909_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2004.10.007","article-title":"Cytochrome P450-mediated metabolism of estrogens and its regulation in human","volume":"227","author":"Tsuchiya","year":"2005","journal-title":"Cancer Lett"},{"issue":"7","key":"10.1016\/j.beem.2024.101909_bib103","doi-asserted-by":"crossref","DOI":"10.1210\/en.2004-1248","article-title":"Potential role for human cytochrome P450 3A4 in estradiol homeostasis","volume":"146","author":"Yu","year":"2005","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.beem.2024.101909_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.eprac.2021.12.014","article-title":"Evaluation of renal function in transgender patients after gender-affirming hormone therapy","volume":"28","author":"Jue","year":"2022","journal-title":"Endocr Pract"},{"issue":"1","key":"10.1016\/j.beem.2024.101909_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.eprac.2021.08.009","article-title":"The effect of gender-affirming hormone therapy on serum creatinine in transgender individuals","volume":"28","author":"Maheshwari","year":"2022","journal-title":"Endocr Pract"},{"issue":"9","key":"10.1016\/j.beem.2024.101909_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsxm.2021.06.011","article-title":"Longitudinal changes in liver enzyme levels among transgender people receiving gender affirming hormone therapy","volume":"18","author":"Hashemi","year":"2021","journal-title":"J Sex Med"},{"issue":"5","key":"10.1016\/j.beem.2024.101909_bib107","doi-asserted-by":"crossref","DOI":"10.1093\/ejendo\/lvad052","article-title":"Changes in laboratory results in transgender individuals on hormone therapy: a retrospective study and practical approach","volume":"188","author":"Boekhout-Berends","year":"2023","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2024.101909_bib108","doi-asserted-by":"crossref","DOI":"10.1111\/liv.12899","article-title":"Cyproterone acetate induces a wide spectrum of acute liver damage including corticosteroid-responsive hepatitis: Report of 22 cases","volume":"36","author":"Bessone","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.beem.2024.101909_bib109","article-title":"Cardiovascular disease in transgendered people: a review of the literature and discussion of risk","volume":"8","author":"Seal","year":"2019","journal-title":"JRSM Cardiovasc Dis"},{"issue":"7","key":"10.1016\/j.beem.2024.101909_bib110","doi-asserted-by":"crossref","DOI":"10.1111\/and.12150","article-title":"Venous thrombo-embolism as a complication of cross-sex hormone treatment of male-to-female transsexual subjects: a review","volume":"46","author":"Asscheman","year":"2014","journal-title":"Andrologia"},{"issue":"8","key":"10.1016\/j.beem.2024.101909_bib111","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.32682","article-title":"Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: a systematic review and meta-analysis","volume":"126","author":"Chakraborty","year":"2020","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.beem.2024.101909_bib112","article-title":"Assessing and addressing the risk of venous thromboembolism across the spectrum of gender affirming care: a review","volume":"29","author":"Arrington-Sanders","year":"2023","journal-title":"Endocr Pract"},{"issue":"2","key":"10.1016\/j.beem.2024.101909_bib113","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2019.5135","article-title":"Association of testosterone therapy with risk of venous thromboembolism among men with and without hypogonadism","volume":"180","author":"Walker","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"7","key":"10.1016\/j.beem.2024.101909_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsxm.2021.04.006","article-title":"Risk for venous thromboembolism in transgender patients undergoing cross-sex hormone treatment: a systematic review","volume":"18","author":"Kotamarti","year":"2021","journal-title":"J Sex Med"},{"issue":"2","key":"10.1016\/j.beem.2024.101909_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.beem.2024.101909_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beem.2024.101909_bib117","article-title":"Fulvestrant May Falsely increase 17\u03b2-estradiol levels in immunoassays: a case report of a 57-year-old postmenopausal patient with recurrent estrogen receptor-positive breast cancer","volume":"12","author":"Ding","year":"2022","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.beem.2024.101909_bib118","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyad049","article-title":"Revisiting androgen receptor signaling in breast cancer","volume":"28","author":"Dai","year":"2023","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.beem.2024.101909_bib119","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-020-01168-7","article-title":"The androgen receptor is a tumor suppressor in estrogen receptor\u2013positive breast cancer","volume":"27","author":"Hickey","year":"2021","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.beem.2024.101909_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(24)00004-4","volume":"25","author":"Palmieri","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.beem.2024.101909_bib121","article-title":"Durable response of androgen receptor-positive male breast cancer to goserelin","volume":"22","author":"Azim","year":"2019","journal-title":"J Breast Cancer"},{"issue":"1","key":"10.1016\/j.beem.2024.101909_bib122","doi-asserted-by":"crossref","DOI":"10.1111\/bju.15521","article-title":"Prostate cancer in transgender women: what does a urologist need to know?","volume":"129","author":"Bertoncelli Tanaka","year":"2022","journal-title":"BJU Int"},{"issue":"9","key":"10.1016\/j.beem.2024.101909_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.beem.2024.101909_bib124","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000001089","article-title":"Delayed radical prostatectomy is not associated with adverse oncologic outcomes: implications for men experiencing surgical delay due to the COVID-19 pandemic","volume":"204","author":"Ginsburg","year":"2020","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.beem.2024.101909_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.beem.2024.101909_bib126","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.beem.2024.101909_bib127","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz396","article-title":"Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial","volume":"30","author":"Clarke","year":"2019","journal-title":"Ann Oncol"},{"issue":"10274","key":"10.1016\/j.beem.2024.101909_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(21)00100-8","article-title":"Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme","volume":"397","author":"Langley","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.beem.2024.101909_bib129","doi-asserted-by":"crossref","DOI":"10.1002\/(SICI)1097-0215(19970904)72:5<714::AID-IJC2>3.0.CO;2-V","article-title":"Constitutive co-expression of estrogen and progesterone receptor mRNA in human meningiomas by RT-PCR and response of in vitro cell cultures to steroid hormones","volume":"72","author":"Speirs","year":"1997","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.beem.2024.101909_bib130","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74344-x","article-title":"Estrogen hormone replacement therapy in incidental intracranial meningioma: a growth-rate analysis","volume":"10","author":"Dresser","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.beem.2024.101909_bib131","doi-asserted-by":"crossref","DOI":"10.1038\/sj.bjc.6605997","article-title":"Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients","volume":"104","author":"Nieuwenhuis","year":"2011","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.beem.2024.101909_bib132","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.21553","article-title":"Estrogen receptor-\u03b2 expression in extraabdominal fibromatoses: an analysis of 40 cases","volume":"106","author":"Deyrup","year":"2006","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.beem.2024.101909_bib133","doi-asserted-by":"crossref","DOI":"10.1007\/s40142-021-00201-6","article-title":"Considerations in management for trans and gender diverse patients with inherited cancer risk","volume":"9","author":"Coad","year":"2021","journal-title":"Curr Genet Med Rep"},{"key":"10.1016\/j.beem.2024.101909_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2024.02.002","article-title":"Fertility potential and gonadal function in survivors of reduced-intensity hematopoietic stem cell transplantation","author":"Rotz","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"1","key":"10.1016\/j.beem.2024.101909_bib135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s44276-023-00002-0","article-title":"UK recommendations for the management of transgender and gender-diverse patients with inherited cancer risks","volume":"1","author":"Giblin","year":"2023","journal-title":"BJC Rep"},{"issue":"6","key":"10.1016\/j.beem.2024.101909_bib136","article-title":"Creating breast and gynecologic cancer guidelines for transgender patients with BRCA mutations","volume":"138","author":"Bedrick","year":"2021","journal-title":"Obstet Gynecol"}],"container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X24000630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X24000630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T20:46:48Z","timestamp":1728334008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X24000630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":136,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1521690X24000630"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2024.101909","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The implications of hormone treatment for cancer risk, screening and treatment in transgender individuals","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2024.101909","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101909"}}